Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review

被引：71
作者：
Kulkarni, Abhijeet D. [1 ]
Vanjari, Yogesh H. [1 ]
Sancheti, Karan H. [1 ]
Belgamwar, Veena S. [2 ]
Surana, Sanjay J. [3 ]
Pardeshi, Chandrakantsing V. [1 ]
机构：
[1] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut, Ind Pharm Lab, Shirpur 425405, Maharashtra, India
[2] RTM Nagpur Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India
[3] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmacognosy, Shirpur, Maharashtra, India
来源：
JOURNAL OF DRUG TARGETING | 2015年 / 23卷 / 09期
关键词：
Blood-brain barrier; brain-blood ratio; nanomedicines; nanotechnology; nasal drug delivery; neurodegenerative disorders; nose to brain; Parkinson's disease; CENTRAL-NERVOUS-SYSTEM; INTRANASAL CARRIERS; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; P-GLYCOPROTEIN; BASAL GANGLIA; LEWY BODIES; IN-VITRO; NANOPARTICLES; THERAPY;
D O I：
10.3109/1061186X.2015.1020809
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Nose to brain delivery of neurotherapeutics have been tried by several researchers to explore the virtues of this route viz. circumvention of BBB, avoidance of hepatic metabolism, practicality, safety, ease of administration and non-invasiveness. Nanoparticle (NP) therapeutics is an emerging modality for the treatment of Parkinson's disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy and/or bioavailability of neurotherapeutics. This review presents a concise incursion into the nanomedicines suitable for PD therapy delivered via naso-brain transport. Clinical signs of PD, its pathophysiology, specific genetic determinants, diagnosis and therapy involved have been hashed out. Properties of brain-targeting NPs, transport efficacy and various nanocarriers developed so far also been furnished. In our opinion, nanotechnology-enabled naso-brain drug delivery is an excellent means of delivering neurotherapeutics and is a promising avenue for researchers to develop new formulations for the effective management of PD.
引用
收藏
页码：775 / 788
页数：14
相关论文
共 97 条
  • [11] Scientific rationale for the development of gene therapy strategies for Parkinson's disease
    Bjorklund, Tomas
    Kirik, Deniz
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2009, 1792 (07): : 703 - 713
  • [12] Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism
    Bonifati, V
    Rizzu, P
    van Baren, MJ
    Schaap, O
    Breedveld, GJ
    Krieger, E
    Dekker, MCJ
    Squitieri, F
    Ibanez, P
    Joosse, M
    van Dongen, JW
    Vanacore, N
    van Swieten, JC
    Brice, A
    Meco, G
    van Duijn, CM
    Oostra, BA
    Heutink, P
    [J]. SCIENCE, 2003, 299 (5604) : 256 - 259
  • [13] Stanley Fahn Lecture 2005:: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered
    Braak, Heiko
    Bohl, Juergen R.
    Muller, Christian M.
    Rub, Udo
    de Vos, Rob A. I.
    Del Tredici, Kelly
    [J]. MOVEMENT DISORDERS, 2006, 21 (12) : 2042 - 2051
  • [14] Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
    Brambilla, Davide
    Le Droumaguet, Benjamin
    Nicolas, Julien
    Hashemi, S. Hossein
    Wu, Lin-Ping
    Moghimi, S. Moein
    Couvreur, Patrick
    Andrieux, Karine
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (05) : 521 - 540
  • [15] INFLUENCE OF AGE AND TIME INTERVAL BETWEEN DEATH AND AUTOPSY ON DOPAMINE AND 3-METHOXYTYRAMINE LEVELS IN HUMAN BASAL GANGLIA
    CARLSSON, A
    WINBLAD, B
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1976, 38 (3-4) : 271 - 276
  • [16] Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats
    Chen, Jian
    Wang, Xiaomei
    Wang, Juan
    Liu, Guangli
    Tang, Xing
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 68 (03) : 694 - 700
  • [17] SEPT5_v2 is a parkin-binding protein
    Choi, P
    Snyder, H
    Petrucelli, L
    Theisler, C
    Chong, M
    Zhang, Y
    Lim, K
    Chung, KKK
    Kehoe, K
    D'Adamio, L
    Lee, JM
    Cochran, E
    Bowser, R
    Dawson, TM
    Wolozin, B
    [J]. MOLECULAR BRAIN RESEARCH, 2003, 117 (02): : 179 - 189
  • [18] The cell biology of α-synuclein -: A sticky problem?
    Cole, NB
    Murphy, DD
    [J]. NEUROMOLECULAR MEDICINE, 2002, 1 (02) : 95 - 109
  • [19] Brain distribution of ribavirin after intranasal administration
    Colombo, Gaia
    Lorenzini, Luca
    Zironi, Elisa
    Galligioni, Viola
    Sonvico, Fabio
    Balducci, Anna Giulia
    Pagliuca, Giampiero
    Giuliani, Alessandro
    Calza, Laura
    Scagliarini, Alessandra
    [J]. ANTIVIRAL RESEARCH, 2011, 92 (03) : 408 - 414
  • [20] The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration
    Corti, O
    Hampe, C
    Koutnikova, H
    Darios, F
    Jacquier, S
    Prigent, A
    Robinson, JC
    Pradier, L
    Ruberg, M
    Mirande, M
    Hirsch, E
    Rooney, T
    Fournier, A
    Brice, A
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (12) : 1427 - 1437
12345678910